-+ 0.00%
-+ 0.00%
-+ 0.00%

JUNSHI BIOSCIENCES ANNOUNCES ACCEPTANCE OF THE SUPPLEMENTAL NEW DRUG APPLICATION OF TORIPALIMAB (SUBSUTANEOUS INJECTION) FOR THE 1ST-LINE TREATMENT OF HER2-EXPRESSING UROTHELIAL CARCINOMA

Reuters·10/29/2026 00:25:40

Please log in to view news